Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51

Abstract Background Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patients. In contrast, combination therapy has proven to be an effective stra...

Full description

Bibliographic Details
Main Authors: Jung Ok Lee, Min Ju Kang, Won Seok Byun, Shin Ae Kim, Il Hyeok Seo, Jeong Ah. Han, Ji Wook Moon, Ji Hae Kim, Su Jin Kim, Eun Jung Lee, Serk In Park, Sun Hwa Park, Hyeon Soo Kim
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Breast Cancer Research
Subjects:
Cisplatin resistance
Metformin
RAD51
TNBC
Combination therapy
Online Access:http://link.springer.com/article/10.1186/s13058-019-1204-2

Internet

http://link.springer.com/article/10.1186/s13058-019-1204-2

Similar Items